Boots registered a twelfth consecutive quarter of retail market share growth, with a reported retail sales increase of 5.9 per cent for the three months
ending on 29 February 2024.
This impressive growth comes on top of a 16 per cent increase recorded during the same period in the previous year, the UK's leading health and beauty retailer
revealed.
Strong growth was observed across digital platforms, namely Boots.com and the Boots app, with a 16.8 per cent surge in digital sales, particularly driven
by "strong sales of beauty and personal care products."
The growth of in-store sales remained consistent, registering a 4.5 per cent increase, with flagship, shopping center, and travel stores demonstrating
particularly strong performance.
The Association of the British Pharmaceutical Industry (ABPI) has proposed a Voluntary Scheme for Pricing, Access and Growth (VPAG) that aims to deliver a
sustainable approach to medicines provision and maximise the growth potential of the UK life sciences industry.
It has published the industry's vision for a new agreement with the government which will deliver for patients, the NHS and the economy.
VPAG also includes measures to ensure rapid patient access and adoption of new medicines, as well as opportunities to improve health outcomes and productivity for
the whole country.
The association's proposals consist of four key areas: restoring an internationally competitive commercial environment for life sciences; supporting UK clinical
research and R&D; ensuring rapid patient access and uptake of new medicines; and improving population health and productivity through health innovation.
The proposal would deliver over £1bn a year to the NHS - around £300m more than the average delivered under the old scheme before 2023, and comfortably more than the
highest contributions ever made before the pandemic.
protein helps your hair grow and lose weight -Researchers have showed how hair growth activated fat tissue growth within the skin below the follicle may lead to the development of a cream to dissolve fat. particularly, the protein that activated follicle growth was shown to conjointly inhibit fat production
Boots witnessed a 'record-breaking' performance for beauty driving retail sales with a growth of 16 per cent in the three months to 28 February 2023.
The beauty category delivered a record January, and premium beauty saw its biggest ever sales week in December. Skincare reported three consecutive weeks of record
sales in December driven by the 'expert skincare' category in which brands including No7, La Roche-Posay, CeraVe and Eucerin proved popular.
Boots beauty transformation strategy continued with 19 new beauty halls opened in Q2 and the 170th store to receive a beauty makeover opening at Westfield White City
post-period end. Boots now stocks over 500 big name and cult beauty brands and exclusively sells the UK's leading skincare brand, No7.
The business reported its eighth consecutive quarter of market share growth with gains across all categories, led by beauty - the stand-out performer of the quarter.
Footfall, basket size and the number of Advantage Card customers all increased, as more people chose to shop at Boots. The Christmas period was particularly strong
with retail sales in the five weeks to 31 December up 17.4% and outperforming the market.
Boots further expanded its value offering in the quarter, announcing its biggest ever savings as part of its continued focus on the affordability of life's essentials.
This included the addition of 60 new products to the Boots Everyday label as well as the extension of its Price Advantage scheme, which has to date resulted in £30
million of customer savings and now includes discounts on over 800 products every month.
Online pharmacy PillTime has taken a step to boost its prescription growth by implementing new Patient Medication Record (PMR) system Titan in its
state-of-the-art premises.
PillTime moved to new, expanded 26,000sqft premises in Cribbs Causeway on the edge of Bristol earlier this year, where it has also installed state-of-the-art
robotics in a bid to significantly enhance future productivity and capacity.
Teething problems over Easter weekend saw PillTime struggling to seamlessly integrate all the new systems and processes while physically moving premises which
affected service delivery and customer support.
However, CEO Leighton Humphreys was supported by Tariq Muhammad, CEO of Invatech Health, who is a former community pharmacist and has worked with independent
pharmacies around the UK as well as larger online businesses, to integrate Titan into their workflows.
Alongside integration work, Muhammad and his team supported PillTime with necessary design, governance and pharmacy expertise as the company struggled to meet its
usual high standards for dispensing medicines to patients.
The 'Life and Health Sciences Launchpad' has been introduced to focus on the precision medicine sector.
It would help businesses and researchers to level up their impact on economic growth within the region.
The launchpad has been funded by Innovate UK, part of UK Research and Innovation (UKRI).
Kerry Curran, Director of GB & EU Trade in the Department for the Economy hailed the decision to support NI's "trailblazing" sector.
She said: "Life and Health Science, including our highly innovative precision medicine cluster, is an area the Department is also prioritising through its
10X Economy Vision, and this Launchpad represents a further endorsement of the world-leading growth potential of precision medicine, and indeed life and
health science, in Northern Ireland.
Well Pharmacy's parent company, Bestway Group, announced on Wednesday (20 March) that it recorded a five per cent growth in revenues to £4.74 billion for
the year ending June 2023, alongside a pre-tax profit of £420.9 million.
During the year, the company also completed acquisition of Lexon UK Holdings, a leading pharmaceutical wholesaler serving over 3,000 retail pharmacy customers
across the UK and Eire.
Furthermore, the Group completed the construction of two cement plants in Pakistan, bringing its total cement manufacturing capacity to 15.3 million tonnes per
annum.
Sir Anwar Pervez OBE, founder and chairman of Bestway Group, expressed optimism about the new business year and said: "The Group has continued on its growth
trajectory in 2023 and we are confident that our businesses will continue to gain share within their respective markets during 2024."
A pioneering study looking into the possibility of combining existing therapies to slow down cancer growth is showing encouraging early results. Elly Earls reports. A first-of-its-kind medical study at The Care Oncology Clinic on Harley Street, London, has started work on evaluating whether the use of a combination of safe, tolerable, existing, generic therapies could slow down cancer growth and improve survival times in patients for whom other treatments are no longer available or working.
British pharmaceutical giant GlaxoSmithKline beat first-quarter sales and earnings forecasts on Wednesday (April 27), helped by demand for its Covid-19 therapy
and shingles vaccine, as the company moves towards the July separation of its consumer health business.
Profit after tax jumped 68 percent to £1.8 billion ($2.3 billion, 2.1 billion euros) compared with the start of 2021.
Sales climbed 32 percent to almost £9.8 billion.
"We have delivered strong first-quarter results in this landmark year for GSK, as we separate consumer healthcare and start a new period of sustained growth," chief
executive Emma Walmsley said in the earnings statement.
"Our results reflect further good momentum across speciality medicines and vaccines, including the return to strong sales growth for Shingrix and continuing pipeline progress."
The shingles vaccine generated £698 million in quarterly sales, beating analyst estimates of 528 million.
Walmsley is seeking to reshape GSK after facing fierce investor criticism over the company's delay in producing Covid jabs and treatments.
Leading pharmaceutical wholesaler Lexon UK has completed a £60 million refinancing deal with HSBC UK to help meet its growth targets in 2022 and beyond.
The asset based lending facility will support Lexon's business strategy, including capital expenditure in areas such as new technology and business development.
Founded in 1995, the Redditch-based supplier has distribution centres in Leeds, Durham and Dublin, supporting thousands of independent pharmacies.
Nimesh Sodha, director at Lexon, said: "We are delighted to have completed this deal - it will help Lexon grow and continue to support independent pharmacies across the UK, as we have done for many years, in fresh and exciting ways.
Consumer goods giant Unilever signalled on Monday (January 17) it would pursue a deal for GlaxoSmithKline's consumer healthcare business, calling it a "strong strategic fit" after its £50 billion offer was refused.
GSK confirmed on Saturday that it had rejected three approaches from the Dove-soap maker, adding it intended to stick to its own plan to spin off the business as a separate company later this year.
"GSK Consumer Healthcare would be a strong strategic fit," Unilever said in a statement as it unveiled a strategy update in the wake of the weekend's takeover news.
Unilever said it was "committed to accelerating the company's growth and repositioning the portfolio into higher growth categories.
"As a result of the reporting of Unilever's interest in GSK Consumer Healthcare, we are today bringing forward a planned update, setting out the strategic direction that the company is pursuing," Unilever said.
Ceuta Group, a global brand building business providing end-to-end outsourcing services in the health and wellness industry has appointed David Wright as a
non-executive board director.
With extensive experience of leading global consumer healthcare companies, David joins Ceuta Group following five years as CEO/President of global pharmaceutical
company, HRA Pharma and six years as Global Head of Boehringer Ingelheim's consumer business.
During his time at HRA Pharma and Boehringer Ingelheim GmBH, David led both companies through substantial organisational and strategy re-design which led to
sustainable growth and profitability.
The company said: "David has a strong belief that combining the right structure, operational priorities and processes, with a strong focus on company culture, are
critical factors in building successful businesses. This approach saw him lead a period of transformation at HRA Pharma resulting in the company's successful
acquisition by Perrigo Company plc."
David will take an active role on the Ceuta Group Board supporting and building the company's strategic vision and priorities. He will also help shape the company's
growth plans on an operational level to ensure Ceuta Group continues to meet client's needs today and into the future.
Panadol launched a new purpose-led brand idea as part of a multi-channel campaign across Great Britain and Ireland. With nine out of 10 people suffering
"everyday pain" and 65% of people saying they can't be happy when they are in pain[1], globally, the campaign reiterates the brand's commitment to holistic pain
management by focusing on the acute pain recovery journey.
Rooted in deep consumer understanding, the campaign idea celebrates that never-talked-about moment of realisation when you start to feel the release from pain.
The new brand idea will bring to life the emotional transformation that those suffering from acute pain undergo, emphasising the role that Panadol can play in
alleviating their pain.
The Panadol campaign follows a period of strong sales growth for the brand, outperforming the category's own expansion by more than double[2].
This has been driven by shoppers who are searching for fast and effective pain relief products, such as Panadol's hero variants, including Panadol Extra Advance
Tablets (paracetamol, caffeine), which has seen its growth almost doubled[3], as well as Panadol Advance Tablets (paracetamol) and Panadol Extra Advance Tablets.
Monica Michalopoulou, GBI Marketing Director, said: "After two years of pandemic restrictions, now more than ever, people want to get back to their normal lives
and to the people they love. But with pain preventing many of us from connecting with those we love or from doing the things we enjoy the most, we want to help
consumers by understanding their pain journey and reassuring them on the treatments we can provide. This "Release" moment is so important for pain sufferers, and we hope our new brand campaign can shine a light on the role that Panadol can play in pain relief".
Ceuta Group has appointed Michael Yates as chief operating officer (COO).
In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services
and unlock new opportunities for its clients.
Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior
commercial and managing director roles across Europe, Africa and Asia.
During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well
as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene.
With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets
across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.
The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the
next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June).
The paper details how a financially sustainable VPAS can support widened medicines access to patients.
VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI).
The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues.
Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to
26.5 per cent.
"The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme,
data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the
association.
Pharmacies have administered more than five million flu vaccinations under the national flu vaccination service in 2022/23, revealed the advanced service flu
report published by the NHS Business Services Authority (NHSBSA).
According to the report, 5,007,578 million vaccinations has been administered by community pharmacies in 2022/23. Whilst in 2021/22 the total number of vaccines
administered in community pharmacies was 4.85 million.
The service has continued to achieve year-on-year growth in the number of vaccinations administered since it launched in 2015.
Commenting on the end-of-season figures, Alastair Buxton, Director of NHS Services, Community Pharmacy England said: "This season's flu vaccination figures are yet
another example of the incredible contribution that our members and their teams make to protect the public and the NHS as part of a key public health programme.
"Given the significant financial and workforce pressures that our members continue to face, this year on year growth is a fantastic achievement and a testament to
their hard work and dedication.
The Company Chemists Association (CCA)'s workforce finding showed that by 2024 eight years' worth of growth of the pharmacist workforce will have been
funnelled away from community pharmacies.
"In 2019, when NHS leaders realised they were unable to find enough GPs to meet the public's needs, they hastily decided to recruit pharmacists and other
healthcare professionals to fill the gaps. This was implemented without any corresponding efforts to increase the supply of pharmacists, creating huge shortages,"
said CCA.
"The bulk of the NHS's recruitment drive was paid for using additional money ringfenced by the NHS - the £2.4bn Additional Roles Reimbursement Scheme (ARRS). We
estimate over the life course of ARRS funding (2019-2024), the equivalent of eight years of growth in the number of pharmacists in England will have been funnelled
directly into primary care at the expense of other sectors.
At the current rate, CCA estimate that community pharmacy will have experienced the equivalent of three fallow years by 2024.
To ensure the pharmacy network is protected and able to take pressure off other parts of the NHS, there are several urgent measures which must be implemented.
Countering the impact of primary care recruitment: Community pharmacists should be commissioned to provide 'packages of care' on behalf of GPs, rather than taking
pharmacists away from accessible high street settings.
The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer.
Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a
combined directorate accountable for education, membership, philanthropy, and business development.
He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members.
Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting
corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior
manager experience at the RAC and at British Airways.
Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience
and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable
the organisation to deliver a dynamic offering for our members.
The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes
a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for
crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations.
A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health
and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023.
Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway.
"We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and
competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the
next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."
The Department of Health and Social Care (DHSC), NHS England and the Association of the British Pharmaceutical Industry (ABPI) have reached an agreement
on the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
The landmark deal will save the NHS £14 billion over 5 years in medicines costs, boost the nation's health, and support research investment.
The new VPAG scheme, which will be a non-contractual voluntary agreement between DHSC and ABPI, will run for 5 years from 1 January 2024 until 31 December 2028.
It will double the annual allowed growth of sales of branded medicines from two per cent per year in 2024 to four per cent per year by 2027.